<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Drugs R D</journal-id><journal-id journal-id-type="iso-abbrev">Drugs R D</journal-id><journal-title-group><journal-title>Drugs in R&#x00026;D</journal-title></journal-title-group><issn pub-type="ppub">1174-5886</issn><issn pub-type="epub">1179-6901</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28074334</article-id><article-id pub-id-type="pmc">5318338</article-id><article-id pub-id-type="publisher-id">170</article-id><article-id pub-id-type="doi">10.1007/s40268-016-0170-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title>Saliva Versus Plasma Bioequivalence of Azithromycin in Humans: Validation of Class I Drugs of the Salivary Excretion Classification System</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Idkaidek</surname><given-names>Nasir</given-names></name><address><email>nidkaidek@uop.edu.jo</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Arafat</surname><given-names>Tawfiq</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Hamadi</surname><given-names>Hazim</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Hamadi</surname><given-names>Salim</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Al-Adham</surname><given-names>Ibrahim</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0640 2983</institution-id><institution-id institution-id-type="GRID">grid.412494.e</institution-id><institution>Faculty of Pharmacy, </institution><institution>Petra University, </institution></institution-wrap>Amman, Jordan </aff></contrib-group><pub-date pub-type="epub"><day>10</day><month>1</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>1</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>3</month><year>2017</year></pub-date><volume>17</volume><issue>1</issue><fpage>219</fpage><lpage>224</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Aim</title><p>The aim of this study was to compare human pharmacokinetics and bioequivalence metrics in saliva versus plasma for azithromycin as a model class I drug of the Salivary Excretion Classification System (SECS).</p></sec><sec><title>Methods</title><p>A pilot, open-label, two-way crossover bioequivalence study was done, and involved a single 500-mg oral dose of azithromycin given to eight healthy subjects under fasting conditions, followed by a 3-week washout period. Blood and unstimulated saliva samples were collected over 72&#x000a0;h and deep frozen until analysis by a validated liquid chromatography with mass spectroscopy method. The pharmacokinetic parameters and bioequivalence metrics of azithromycin were calculated by non-compartment analysis using WinNonlin V5.2. Descriptive statistics and dimensional analysis of the pharmacokinetic parameters of azithromycin were performed using Microsoft Excel. PK-Sim V5.6 was used to estimate the effective intestinal permeability of azithromycin.</p></sec><sec><title>Results and Discussion</title><p>No statistical differences were shown in area under the concentration curves to 72&#x000a0;h (AUC<sub>0&#x02013;72</sub>), maximum measured concentration (<italic>C</italic>
<sub>max</sub>) and time to maximum concentration (<italic>T</italic>
<sub>max</sub>) between test and reference azithromycin products (<italic>P</italic>&#x000a0;&#x0003e;&#x000a0;0.05) in the saliva matrix and in the plasma matrix. Due to the high intra-subject variability and low sample size of this pilot study, the 90% confidence intervals of AUC<sub>0&#x02013;72</sub> and <italic>C</italic>
<sub>max</sub> did not fall within the acceptance range (80&#x02013;125%). However, saliva levels were higher than that of plasma, with a longer salivary <italic>T</italic>
<sub>max</sub>. The mean saliva/plasma concentration of test and reference were 2.29 and 2.33, respectively. The mean&#x000a0;&#x000b1;&#x000a0;standard deviation ratios of saliva/plasma of AUC<sub>0&#x02013;72</sub>, <italic>C</italic>
<sub>max</sub> and <italic>T</italic>
<sub>max</sub> for test were 2.65&#x000a0;&#x000b1;&#x000a0;1.59, 1.51&#x000a0;&#x000b1;&#x000a0;0.49 and 1.85&#x000a0;&#x000b1;&#x000a0;1.4, while for the reference product they were 3.37&#x000a0;&#x000b1;&#x000a0;2.20, 1.57&#x000a0;&#x000b1;&#x000a0;0.77 and 2.6&#x000a0;&#x000b1;&#x000a0;1.27, respectively. A good correlation of <italic>R</italic>&#x000a0;=&#x000a0;0.87 between plasma and saliva concentrations for both test and reference products was also observed. Azithromycin is considered a class I drug based on the SECS, since it has a high permeability and high fraction unbound, and saliva sampling could be used as an alternative to plasma sampling to characterize its pharmacokinetics and bioequivalence in humans when adequate sample size is used.</p></sec></abstract><funding-group><award-group><funding-source><institution>Petra University</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing Switzerland 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="FPar1"><title>Key Points</title><p>
<table-wrap id="Taba"><table frame="hsides" rules="groups"><tbody><tr><td align="left">Saliva sampling offers an easy and non-invasive method as compared with plasma sampling.</td></tr><tr><td align="left">Azithromycin pharmacokinetics and bioequivalence metrics in saliva were compared with plasma, and a good correlation was demonstrated.</td></tr><tr><td align="left">Azithromycin is considered a class I drug based on the Salivary Excretion Classification System (SECS), and saliva sampling could be used as an alternative to plasma sampling to characterize the drug&#x02019;s pharmacokinetics and bioequivalence in humans.</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Salivary excretion of some drugs has been reported previously as a good indicator for drug bioavailability, therapeutic drug monitoring [<xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>], pharmacokinetics [<xref ref-type="bibr" rid="CR7">7</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>] and also drug abuse [<xref ref-type="bibr" rid="CR12">12</xref>]. Saliva sampling offers a simple, non-invasive and cheap method as compared [<xref ref-type="bibr" rid="CR13">13</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>] with plasma sampling, yet needs special attention so that no drug residue is left in the mouth after dosing. According to the Salivary Excretion Classification System (SECS), class I drugs of high intestinal permeability and low protein binding, such as paracetamol, are subjected to salivary excretion. Class II drugs of low permeability and low protein binding, such as metformin, are subjected to salivary excretion since low permeability is counterbalanced by low protein binding. Class III drugs of high intestinal permeability and high protein binding, such as cinacalcet, are subjected to salivary excretion since high protein binding is counterbalanced by high permeability. Class IV drugs of low intestinal permeability and high protein binding, such as montelukast, are not subjected to salivary excretion [<xref ref-type="bibr" rid="CR1">1</xref>]. In addition, drug analysis in the clean saliva matrix is simple and can be done using the same method of analysis as plasma matrix. Azithromycin is a semi-synthetic 15-member azalide antibiotic derived from erythromycin. It is characterized by better acid stability associated with more reliable and greater oral bioavailability, more extensive tissue penetration, and significantly longer elimination half-life compared with erythromycin. Azithromycin is effective against Gram-positive and Gram-negative pathogens. Azithromycin is commonly used for the treatment and prophylaxis of respiratory tract infection, skin and soft tissue infection, and sexually transmitted diseases [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>].</p></sec><sec id="Sec2"><title>Objectives</title><p>The aim of this study was to compare human pharmacokinetics and bioequivalence metrics in saliva versus plasma for azithromycin as a model class I drug of the SECS.</p></sec><sec id="Sec3"><title>Experimental</title><sec id="Sec12"><title>Design</title><p>Plasma pharmacokinetics under fasted state conditions were compared with saliva pharmacokinetics in a two-way cross-over truncated design study. The pilot bioequivalence study was conducted on in eight healthy human volunteers at Al-Hilal Hospital as per the International Council for Harmonization, Good Clinical Practice, and Helsinki declaration guidelines, after Jordan Food and Drug Administration approvals.</p><p>Oral dosing of 500&#x000a0;mg azithromycin test formula (Azox<sup>&#x000ae;</sup> tablet, batch #150912, expiry date 09/2018) or reference formula (Zithromax tablet, batch #315704, expiry date 03/2018) with 240&#x000a0;mL of water was given after 10&#x000a0;h overnight fasting without dietary restrictions.</p><p>Plasma and resting unstimulated saliva samples were collected at 0, 0.33, 0.66, 1.00, 1.50, 2.00, 2.5, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 8.00, 10.00, 12.00, 24.00 and 48.00 and truncated at 72.00&#x000a0;h during each study phase. Mouth checking and thorough rinsing of the mouth was done prior to first saliva sampling to avoid contamination of saliva samples by any drug residues. All samples were deep frozen until assayed by the validated liquid chromatography with mass spectroscopy (LC-MS) assay method (detailed below).</p><p>Medical history, vital signs, physical examination and laboratory safety test results showed no evidence of clinically significant deviation from normal medical condition as evaluated by the clinical investigator.</p></sec><sec id="Sec4"><title>Assay Methodology</title><p>Plasma and saliva samples were deep frozen until assayed by validated LC-MS assay method. A Hypersil BDS C18 column at 30&#x000a0;&#x000b0;C was used with roxithromycin as the internal standard. The mobile phase was 45% 0.01&#x000a0;M ammonium acetate plus 0.1% acetic acid and 55% methanol. The flow rate was 0.5&#x000a0;mL/min, with an ambient auto-sampler temperature. The extraction procedure was as follows:<list list-type="bullet"><list-item><p>Pipette 300&#x000a0;&#x003bc;L of spiked/blank plasma sample into a previously labeled test tube.</p></list-item><list-item><p>Add 50&#x000a0;&#x003bc;L of internal standard (400&#x000a0;ng roxithromycin/mL), and vortex for 15&#x000a0;s.</p></list-item><list-item><p>Add 150&#x000a0;&#x003bc;L of extraction buffer for plasma samples only (0.1&#x000a0;M sodium carbonate), and vortex for 30&#x000a0;s.</p></list-item><list-item><p>Add 5&#x000a0;mL of extraction solvent (MTBE), and vortex for 2&#x000a0;min.</p></list-item><list-item><p>Centrifuge the sample for 2&#x000a0;min at 4400&#x000a0;rpm.</p></list-item><list-item><p>Freeze the sample for about 30&#x000a0;min then decant the supernatant in a clean evaporating glass tube.</p></list-item><list-item><p>Evaporate the extraction solvent by compressed air in water bath at 40&#x000a0;&#x000b0;C (this step should be conducted in the fume hood), reconstitute the residue with 250&#x000a0;&#x003bc;L of reconstitution solution (50 MeOH:50 water) plus 0.1% acetic acid, and vortex for 1&#x000a0;min.</p></list-item><list-item><p>Transfer the sample into a flat bottom inserts vial, and inject into the instrument.</p></list-item></list>
</p><p>Intra-day coefficient of variation was 3%, inter-day accuracy range was 93.228&#x02013;105.140%, inter-day precision range was 6.65&#x02013;13.204% and linear range was 5&#x02013;450&#x000a0;ng/mL.</p></sec><sec id="Sec5"><title>Data Analysis</title><sec id="Sec6"><title>Pharmacokinetic Analysis</title><p>Individual pharmacokinetic parameters for drug concentration in both saliva and plasma samples were calculated by non-compartmental analysis using WinNonlin V5.2. Pharmacokinetic parameters were area under the concentration curve to 72&#x000a0;h (AUC<sub>0&#x02013;72</sub>), maximum measured concentration (<italic>C</italic>
<sub>max</sub>) and time to maximum concentration (<italic>T</italic>
<sub>max</sub>). The elimination phase was not clear enough in the truncated design to calculate elimination parameters such as half-life and elimination rate constant.</p></sec><sec id="Sec7"><title>Dimensional and Correlation Analysis</title><p>The following dimensionless saliva/plasma ratios were calculated in Microsoft Excel:<list list-type="bullet"><list-item><p>AUC<sup>*</sup>&#x000a0;=&#x000a0;saliva AUC<sub>t</sub>/plasma AUC<sub>t</sub>
</p></list-item><list-item><p>
<italic>T</italic>
<sub>max</sub>
<sup>*</sup>&#x000a0;=&#x000a0;saliva <italic>T</italic>
<sub>max</sub>/plasma <italic>T</italic>
<sub>max</sub>
</p></list-item><list-item><p>
<italic>C</italic>
<sub>max</sub>
<sup>*</sup>&#x000a0;=&#x000a0;saliva <italic>C</italic>
<sub>max</sub>/plasma <italic>C</italic>
<sub>max</sub>
</p></list-item><list-item><p>
<italic>C</italic>
<sup>*</sup>&#x000a0;=&#x000a0;saliva concentration/plasma concentration&#x000a0;=&#x000a0;<italic>C</italic>
<sub>s</sub>/<italic>C</italic>
<sub>p</sub>
</p></list-item></list>
</p><p>Correlation analysis was performed using Excel to correlate average <italic>C</italic>
<sub>s</sub> versus average <italic>C</italic>
<sub>p</sub> values up to median <italic>T</italic>
<sub>max</sub> of the reference product.</p></sec><sec id="Sec8"><title>Bioequivalence and Statistical Analysis</title><p>Analysis of variance, 90% confidence intervals, and intra-subject variability estimates for primary pharmacokinetic parameters for test and reference products after logarithmic transformation were calculated by WinNonlin V5.2. Statistical comparisons were also done using parametric <italic>t</italic> tests for AUC and <italic>C</italic>
<sub>max</sub>, and the non-parametric Wicoxon test for <italic>T</italic>
<sub>max</sub>.</p></sec><sec id="Sec9"><title>Absorption Kinetics</title><p>The Nelder&#x02013;Mead algorithm of the Parameter Estimation module, using the PK-Sim program V5.6, was used to calculate azithromycin intestinal permeability (<italic>P</italic>
<sub>eff</sub>) by searching for the best parameter values that produced a plasma concentration that matched the actual plasma concentration at the same time. The objective function is the weighted sum of squared differences of the observed and model predicted values.</p></sec></sec></sec><sec id="Sec10"><title>Results and Discussion</title><p>Azithromycin plasma and saliva mean concentrations are shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. It is noticed that saliva concentrations are much higher than plasma concentrations. However, saliva profiles in test and reference products are closely related to those in plasma. The correlation coefficients and coefficients of determination of 0.84&#x02013;0.87 and 0.71&#x02013;0.76 between saliva and plasma concentrations up to median <italic>T</italic>
<sub>max</sub> values of plasma profiles are shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>. This is in agreement with the good correlation shown previously for other drugs [<xref ref-type="bibr" rid="CR1">1</xref>]. Pharmacokinetic parameters of AUC0&#x02013;72, <italic>T</italic>
<sub>max</sub> and <italic>C</italic>
<sub>max</sub> in saliva and plasma are summarized in Tables&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>. No statistical differences were seen for AUC<sub>0&#x02013;72</sub>, <italic>C</italic>
<sub>max</sub> and <italic>T</italic>
<sub>max</sub> between test and reference azithromycin products (<italic>P</italic>&#x000a0;&#x0003e;&#x000a0;0.05) in saliva matrix and in plasma matrix.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Plasma and saliva of azithromycin mean concentrations (conc). <italic>R</italic> reference, <italic>T</italic> test</p></caption><graphic xlink:href="40268_2016_170_Fig1_HTML" id="MO1"/></fig>
<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Correlation of saliva and plasma azithromycin mean concentrations in test and reference</p></caption><graphic xlink:href="40268_2016_170_Fig2_HTML" id="MO2"/></fig>
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Pharmacokinetic parameters of azithromycin test and reference formulations in plasma</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left">Test</th><th align="left">Reference</th><th align="left">
<italic>P</italic> value; paired <italic>t</italic> test</th></tr></thead><tbody><tr><td align="left">AUC<sub>0&#x02013;72</sub> (ng/mL&#x000b7;h)</td><td align="left">2419.47</td><td align="left">2517.0</td><td align="left">0.44</td></tr><tr><td align="left">
<italic>C</italic>
<sub>max</sub> (ng/mL)</td><td align="left">291.30</td><td align="left">328.3</td><td align="left">0.47</td></tr><tr><td align="left">
<italic>T</italic>
<sub>max</sub> (h)</td><td align="left">3.38</td><td align="left">3.2</td><td align="left">0.67*</td></tr></tbody></table><table-wrap-foot><p>*&#x000a0;Wilcoxon test is done for <italic>T</italic>
<sub>max</sub>
</p></table-wrap-foot></table-wrap>
<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Pharmacokinetic parameters of azithromycin of test and reference formulations in saliva</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left">Test</th><th align="left">Reference</th><th align="left">
<italic>P</italic> value; paired <italic>t</italic> test</th></tr></thead><tbody><tr><td align="left">AUC<sub>0&#x02013;72</sub> (ng/mL&#x000b7;h)</td><td align="left">6992.05</td><td align="left">8560.74</td><td align="left">0.35</td></tr><tr><td align="left">
<italic>C</italic>
<sub>max</sub> (ng/mL)</td><td align="left">453.33</td><td align="left">496.69</td><td align="left">0.30</td></tr><tr><td align="left">
<italic>T</italic>
<sub>max</sub> (h)</td><td align="left">5.25</td><td align="left">8.44</td><td align="left">0.15*</td></tr></tbody></table><table-wrap-foot><p>*&#x000a0;Wilcoxon test is done for <italic>T</italic>
<sub>max</sub>
</p></table-wrap-foot></table-wrap>
</p><p>Moreover, bioequivalence metrics and statistical comparisons for primary pharmacokinetic parameters were calculated for both saliva and plasma. The 90% confidence intervals for AUC0&#x02013;72 and <italic>C</italic>
<sub>max</sub> were 45.32&#x02013;117.51 and 63.20&#x02013;113.64, and 65.56&#x02013;117.58 and 52.05&#x02013;134.33% in saliva and plasma, respectively. However, geometric mean ratios of AUC0&#x02013;72 and <italic>C</italic>
<sub>max</sub> in saliva were 84 and 73, and 88 and 83% in plasma. Confidence intervals did not pass in both saliva and plasma because of the low sample size of this pilot study. This is reflected in a high intra-subject variability of 52% and a minimum low study power of 19% in both saliva and plasma.</p><p>Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref> shows observed versus PK-Sim-predicted concentration profiles, indicating good fit. The optimized effective permeability coefficient was 0.0006&#x000a0;cm/s. Azithromycin falls into class I, consistent with published results [<xref ref-type="bibr" rid="CR1">1</xref>], with high permeability (Fa&#x000a0;=&#x000a0;0.99) and high fraction unbound (fu&#x000a0;=&#x000a0;0.71), with good salivary excretion. Moreover, the dimensional analysis presented in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref> shows that saliva to plasma ratios are higher than unity. This is consistent with the higher concentrations and parameter values in saliva as compared to plasma, which makes it easier to measure and trace azithromycin concentrations in saliva.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Observed vs. PK-Sim-predicted plasma concentrations (<bold>a</bold>, <bold>b</bold>)</p></caption><graphic xlink:href="40268_2016_170_Fig3_HTML" id="MO3"/></fig>
<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Saliva/plasma dimensional analysis of test and reference</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Parameter</th><th align="left">Test</th><th align="left">Reference</th></tr></thead><tbody><tr><td align="left">AUC*</td><td align="left">2.65</td><td align="left">3.37</td></tr><tr><td align="left">
<italic>C</italic>
<sub>max</sub>*</td><td align="left">1.51</td><td align="left">1.57</td></tr><tr><td align="left">
<italic>T</italic>
<sub>max</sub>*</td><td align="left">1.85</td><td align="left">2.86</td></tr><tr><td align="left">
<italic>C</italic>*</td><td align="left">2.29</td><td align="left">2.33</td></tr></tbody></table><table-wrap-foot><p>
<italic>AUC</italic> area under the concentration curve, <italic>AUC*</italic> saliva AUC<sub>t</sub>/plasma AUC<sub><italic>t</italic></sub>, <italic>C</italic>
<sub><italic>max</italic></sub> maximum measured concentration, <italic>C</italic>
<sub><italic>max</italic></sub>
<italic>*</italic> saliva <italic>C</italic>
<sub>max</sub>/plasma <italic>C</italic>
<sub>max</sub>, <italic>T</italic>
<sub><italic>max</italic></sub> time to <italic>C</italic>
<sub>max</sub>, <italic>T</italic>
<sub><italic>max</italic></sub>
<italic>*</italic> saliva <italic>T</italic>
<sub>max</sub>/plasma <italic>T</italic>
<sub>max</sub>, <italic>C*</italic> saliva concentration/plasma concentration</p></table-wrap-foot></table-wrap>
</p><p>It is well known that for most antibiotics, serum levels serve as a good surrogate of levels at the site of infection, but for certain classes of antibiotics (e.g., azithromycin, clarithromycin), there is a large difference between serum drug level and level at infection site (10- to 20-fold). Therefore, using the pharmacokinetic data alone is not enough to describe the antimicrobial activity of the drug, and pharmacodynamic parameters should integrate with pharmacokinetic parameters. Integrating the pharmacokinetic parameters with the minimum inhibitory concentration (MIC) gives us three pharmacokinetic/pharmacodynamic parameters that quantify the activity of an antibiotic: the peak/MIC ratio, the <italic>T</italic>&#x000a0;&#x0003e;&#x000a0;MIC, and the 24&#x000a0;h-AUC/MIC ratio. It was found that azithromycin killing activity is best described by 24&#x000a0;h-AUC/MIC calculation [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Since the AUC of azithromycin in saliva is much higher than that of plasma, saliva AUC may be used to calculate the killing activity of azithromycin.</p></sec><sec id="Sec11" sec-type="conclusion"><title>Conclusions</title><p>Azithromycin saliva sampling could be used as an alternative to plasma sampling to characterize the drug&#x02019;s pharmacokinetics and bioequivalence in humans when adequate sample size is used. Further work is needed to fully characterize the salivary excretion of azithromycin following its oral administration using larger sample size and extended sampling time.</p><p>Indeed, it was not our goal to establish bioequivalence, but rather to confirm a concept and to show suitability and validity of saliva instead of plasma in such studies. Saliva sampling has the advantages of being easier to collect and painless compared with plasma sampling. Moreover, saliva sampling can be done at home by patients, in the case of therapeutic drug monitoring, or in a controlled study in hospitals. NASA has conducted several clinical trials in space shuttles using saliva sampling because of its validity and suitability [<xref ref-type="bibr" rid="CR21">21</xref>]. The main disadvantage of saliva samples can be the high intra- and inter-subject variability. However, this can also be accounted for by enrolling a larger number of subjects in the clinical study.</p></sec></body><back><ack><title>Acknowledgements</title><p>This work was done in partial fulfillment of Master of Science requirements at the University of Petra. We thank all staff at Al-Hilal Hospital and the Jordan Center of Pharmaceutical Research.</p></ack><notes notes-type="COI-statement"><title>Compliance with Ethical Standards</title><sec id="FPar2"><title>Conflicts of interest</title><p>Nasir Idkaidek, Tawfiq Arafat, Hazim Hamadi, Salim Hamadi and Ibrahim Al-Adham have no conflicts of interest to declare.</p></sec><sec id="FPar3"><title>Funding</title><p>No funding was received for the preparation of this manuscript. This research was funded by Petra University. WinNonlin was used under an academic license from Pharsight Inc., USA. The PK-Sim program was used under an academic license from BAYER Ltd, Germany.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Idkaidek</surname><given-names>N</given-names></name><name><surname>Arafat</surname><given-names>T</given-names></name></person-group><article-title>Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system</article-title><source>Mol Pharm</source><year>2012</year><volume>9</volume><fpage>2358</fpage><lpage>2363</lpage><pub-id pub-id-type="doi">10.1021/mp300250r</pub-id><pub-id pub-id-type="pmid">22784220</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumann</surname><given-names>RJ</given-names></name></person-group><article-title>Salivary monitoring of antiepileptic drugs</article-title><source>J Pharm Pract</source><year>2007</year><volume>20</volume><fpage>147</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1177/0897190007305139</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danhof</surname><given-names>M</given-names></name><name><surname>Breimer</surname><given-names>D</given-names></name></person-group><article-title>Therapeutic drug monitoring in saliva</article-title><source>Clin Pharmacokinet</source><year>1978</year><volume>3</volume><fpage>39</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.2165/00003088-197803010-00003</pub-id><pub-id pub-id-type="pmid">25155</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drobitch</surname><given-names>RK</given-names></name><name><surname>Svensson</surname><given-names>CK</given-names></name></person-group><article-title>Therapeutic drug monitoring in saliva</article-title><source>Clin Pharmacokinet</source><year>1992</year><volume>23</volume><fpage>365</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.2165/00003088-199223050-00003</pub-id><pub-id pub-id-type="pmid">1478004</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Delgado</surname><given-names>MR</given-names></name></person-group><article-title>Therapeutic drug concentration monitoring using saliva samples</article-title><source>Clin Pharmacokinet</source><year>1999</year><volume>36</volume><fpage>453</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.2165/00003088-199936060-00006</pub-id><pub-id pub-id-type="pmid">10427469</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mucklow</surname><given-names>JC</given-names></name></person-group><article-title>The use of saliva in therapeutic drug monitoring</article-title><source>Ther Drug Monit</source><year>1982</year><volume>4</volume><fpage>229</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1097/00007691-198208000-00001</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adithan</surname><given-names>C</given-names></name><name><surname>Thangam</surname><given-names>J</given-names></name></person-group><article-title>A comparative study of saliva and serum paracetamol levels using a simple spectrophotometric method</article-title><source>Br J Clin Pharmacol</source><year>1982</year><volume>14</volume><fpage>107</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.1982.tb04944.x</pub-id><pub-id pub-id-type="pmid">7104162</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baldo</surname><given-names>M</given-names></name><name><surname>Hunzicker</surname><given-names>G</given-names></name><name><surname>Altamirano</surname><given-names>J</given-names></name><name><surname>Murgu&#x000ed;a</surname><given-names>M</given-names></name><name><surname>Hein</surname><given-names>G</given-names></name></person-group><article-title>Saliva as a noninvasive biological sample to compare bioavailability of phenytoin formulations by LC&#x02013;MS/MS</article-title><source>Int J Pharm Sci Res</source><year>2015</year><volume>6</volume><fpage>3752</fpage></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cawello</surname><given-names>W</given-names></name><name><surname>B&#x000f6;kens</surname><given-names>H</given-names></name><name><surname>Nickel</surname><given-names>B</given-names></name><name><surname>Andreas</surname><given-names>JO</given-names></name><name><surname>Halabi</surname><given-names>A</given-names></name></person-group><article-title>Tolerability, pharmacokinetics, and bioequivalence of the tablet and syrup formulations of lacosamide in plasma, saliva, and urine: saliva as a surrogate of pharmacokinetics in the central compartment</article-title><source>Epilepsia</source><year>2013</year><volume>54</volume><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1111/j.1528-1167.2012.03725.x</pub-id><pub-id pub-id-type="pmid">23148731</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koks</surname><given-names>C</given-names></name><name><surname>Meenhorst</surname><given-names>P</given-names></name><name><surname>Hillebrand</surname><given-names>M</given-names></name><name><surname>Bult</surname><given-names>A</given-names></name><name><surname>Beijnen</surname><given-names>J</given-names></name></person-group><article-title>Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules</article-title><source>Antimicrob Agents Chemother</source><year>1996</year><volume>40</volume><fpage>1935</fpage><lpage>1937</lpage><pub-id pub-id-type="pmid">8843308</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suryawati</surname><given-names>S</given-names></name><name><surname>Santoso</surname><given-names>B</given-names></name></person-group><article-title>Pharmacokinetics of metronidazole in saliva</article-title><source>Int J Clin Pharmacol Ther Toxicol</source><year>1991</year><volume>29</volume><fpage>474</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">1813432</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guinan</surname><given-names>T</given-names></name><name><surname>Ronci</surname><given-names>M</given-names></name><name><surname>Kobus</surname><given-names>H</given-names></name><name><surname>Voelcker</surname><given-names>NH</given-names></name></person-group><article-title>Rapid detection of illicit drugs in neat saliva using desorption/ionization on porous silicon</article-title><source>Talanta</source><year>2012</year><volume>99</volume><fpage>791</fpage><lpage>798</lpage><pub-id pub-id-type="doi">10.1016/j.talanta.2012.07.029</pub-id><pub-id pub-id-type="pmid">22967625</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunes</surname><given-names>LAS</given-names></name><name><surname>Brenzikofer</surname><given-names>R</given-names></name><name><surname>Macedo</surname><given-names>DV</given-names></name></person-group><article-title>Reference intervals for saliva analytes collected by a standardized method in a physically active population</article-title><source>Clin Biochem</source><year>2011</year><volume>44</volume><fpage>1440</fpage><lpage>1444</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2011.09.012</pub-id><pub-id pub-id-type="pmid">21986592</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunes</surname><given-names>S</given-names></name><name><surname>Alessandro</surname><given-names>L</given-names></name><name><surname>Mussavira</surname><given-names>S</given-names></name><name><surname>Sukumaran Bindhu</surname><given-names>O</given-names></name></person-group><article-title>Clinical and diagnostic utility of saliva as a non-invasive diagnostic fluid: a systematic review</article-title><source>Biochemia Medica</source><year>2015</year><volume>25</volume><fpage>177</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.11613/BM.2015.018</pub-id><pub-id pub-id-type="pmid">26110030</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfaffe</surname><given-names>T</given-names></name><name><surname>Cooper-White</surname><given-names>J</given-names></name><name><surname>Beyerlein</surname><given-names>P</given-names></name><name><surname>Kostner</surname><given-names>K</given-names></name><name><surname>Punyadeera</surname><given-names>C</given-names></name></person-group><article-title>Diagnostic potential of saliva: current state and future applications</article-title><source>Clin Chem</source><year>2011</year><volume>57</volume><fpage>675</fpage><lpage>687</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2010.153767</pub-id><pub-id pub-id-type="pmid">21383043</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Javaid</surname><given-names>MA</given-names></name><name><surname>Ahmed</surname><given-names>AS</given-names></name><name><surname>Durand</surname><given-names>R</given-names></name><name><surname>Tran</surname><given-names>SD</given-names></name></person-group><article-title>Saliva as a diagnostic tool for oral and systemic diseases</article-title><source>J Oral Biol Craniofac Res</source><year>2015</year><volume>6</volume><fpage>67</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.jobcr.2015.08.006</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drew</surname><given-names>RH</given-names></name><name><surname>Gallis</surname><given-names>HA</given-names></name></person-group><article-title>Azithromycin&#x02014;spectrum of activity, pharmacokinetics, and clinical applications</article-title><source>Pharmacother: J Hum Pharmacol Drug Ther</source><year>1992</year><volume>12</volume><fpage>161</fpage><lpage>173</lpage></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballow</surname><given-names>CH</given-names></name><name><surname>Amsden</surname><given-names>GW</given-names></name></person-group><article-title>Azithromycin: the first azalide antibiotic</article-title><source>Ann Pharmacother</source><year>1992</year><volume>26</volume><fpage>1253</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1177/106002809202601014</pub-id><pub-id pub-id-type="pmid">1330097</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levison</surname><given-names>ME</given-names></name><name><surname>Levison</surname><given-names>JH</given-names></name></person-group><article-title>Pharmacokinetics and pharmacodynamics of antibacterial agents</article-title><source>Infect Dis Clin North Am</source><year>2009</year><volume>23</volume><fpage>791</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1016/j.idc.2009.06.008</pub-id><pub-id pub-id-type="pmid">19909885</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Bambeke</surname><given-names>F</given-names></name><name><surname>Tulkens</surname><given-names>PM</given-names></name></person-group><article-title>Macrolides: pharmacokinetics and pharmacodynamics</article-title><source>Int J Antimicrob Agents</source><year>2001</year><volume>18</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/S0924-8579(01)00406-X</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Rhie J. The pellet gastric emptying (PGE) test: development of a non-invasive method to assess gastric emptying. Ph.D. Dissertation, University of Michigan. 1996.</mixed-citation></ref></ref-list></back></article>